Subscribe
hailshadow-istockphoto-com
Hailshadow / iStockphoto.com
15 February 2017Asia-Pacific

Hepatitis C drugs face four patent challenges in India

India-based Initiative for Medicines, Access & Knowledge (I-MAK) has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
AbbVie faces hepatitis C patent challenge in India
26 July 2018   In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Asia
AbbVie faces hepatitis C patent challenge in India
26 July 2018   In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More on this story

Asia
AbbVie faces hepatitis C patent challenge in India
26 July 2018   In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB